
Sign up to save your podcasts
Or


Prasad Kulkarni joins Callam Davidson of The Lancet to discuss the safety and immunogenicity of a bivalent conjugate vaccine against typhoid and paratyphoid, following the publication of a phase 1 trial.
Continue this conversation on social!
By The Lancet GroupPrasad Kulkarni joins Callam Davidson of The Lancet to discuss the safety and immunogenicity of a bivalent conjugate vaccine against typhoid and paratyphoid, following the publication of a phase 1 trial.
Continue this conversation on social!

134 Listeners

22 Listeners

0 Listeners

0 Listeners

3 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

21 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners